CN101808645A - 治疗红斑的改良溴莫尼定组合物 - Google Patents

治疗红斑的改良溴莫尼定组合物 Download PDF

Info

Publication number
CN101808645A
CN101808645A CN200880105032A CN200880105032A CN101808645A CN 101808645 A CN101808645 A CN 101808645A CN 200880105032 A CN200880105032 A CN 200880105032A CN 200880105032 A CN200880105032 A CN 200880105032A CN 101808645 A CN101808645 A CN 101808645A
Authority
CN
China
Prior art keywords
compositions according
gel
weight
brimonidine tartrate
erythema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880105032A
Other languages
English (en)
Chinese (zh)
Inventor
克劳斯·特奥巴尔德
克里斯托夫·V·波瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Laboratories LP
Original Assignee
Galderma Laboratories LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Laboratories LP filed Critical Galderma Laboratories LP
Publication of CN101808645A publication Critical patent/CN101808645A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880105032A 2007-08-31 2008-08-29 治疗红斑的改良溴莫尼定组合物 Pending CN101808645A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
US60/967,191 2007-08-31
PCT/US2008/010290 WO2009032223A1 (en) 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110321688XA Division CN102552112A (zh) 2007-08-31 2008-08-29 治疗红斑的改良溴莫尼定组合物

Publications (1)

Publication Number Publication Date
CN101808645A true CN101808645A (zh) 2010-08-18

Family

ID=40407909

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880105032A Pending CN101808645A (zh) 2007-08-31 2008-08-29 治疗红斑的改良溴莫尼定组合物
CN201110321688XA Pending CN102552112A (zh) 2007-08-31 2008-08-29 治疗红斑的改良溴莫尼定组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110321688XA Pending CN102552112A (zh) 2007-08-31 2008-08-29 治疗红斑的改良溴莫尼定组合物

Country Status (12)

Country Link
US (3) US20090061020A1 (enExample)
EP (1) EP2200617A4 (enExample)
JP (1) JP2010537988A (enExample)
KR (1) KR20100055453A (enExample)
CN (2) CN101808645A (enExample)
AR (1) AR068816A1 (enExample)
AU (1) AU2008296948A1 (enExample)
BR (1) BRPI0816097A2 (enExample)
CA (1) CA2698680A1 (enExample)
MX (1) MX2010002392A (enExample)
NO (1) NO20100301L (enExample)
WO (1) WO2009032223A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298451A (zh) * 2010-10-21 2013-09-11 高德美国际公司 溴莫尼定凝胶剂组合物及其使用方法
CN103313700A (zh) * 2010-10-21 2013-09-18 高德美国际公司 外用凝胶剂组合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
WO2010136594A2 (en) * 2009-05-29 2010-12-02 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
EP2493309A4 (en) * 2009-10-26 2013-05-01 Galderma Pharma Sa METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
RU2535008C2 (ru) 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
MX2012010824A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
AU2012217858A1 (en) 2011-02-15 2013-09-05 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
BR112014009210A2 (pt) 2011-10-19 2017-04-18 Galderma Sa método para a redução da vermelhidão facial cutânea
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
WO2015191917A1 (en) 2014-06-11 2015-12-17 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
WO2019014518A1 (en) * 2017-07-14 2019-01-17 Galderma Research And Development METHODS AND COMPOSITIONS FOR REDUCING ADVERSE EFFECTS OF CHEMOTHERAPEUTIC TREATMENTS
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
EP2230910A4 (en) * 2007-12-21 2011-04-13 Galderma Lab Inc PRE-SURGICAL TREATMENT

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298451A (zh) * 2010-10-21 2013-09-11 高德美国际公司 溴莫尼定凝胶剂组合物及其使用方法
CN103313700A (zh) * 2010-10-21 2013-09-18 高德美国际公司 外用凝胶剂组合物
CN103298451B (zh) * 2010-10-21 2016-04-20 高德美国际公司 溴莫尼定凝胶剂组合物及其使用方法

Also Published As

Publication number Publication date
BRPI0816097A2 (pt) 2016-11-01
AU2008296948A1 (en) 2009-03-12
US20120040016A1 (en) 2012-02-16
CN102552112A (zh) 2012-07-11
AR068816A1 (es) 2009-12-09
KR20100055453A (ko) 2010-05-26
JP2010537988A (ja) 2010-12-09
US20120282346A1 (en) 2012-11-08
EP2200617A1 (en) 2010-06-30
NO20100301L (no) 2010-03-25
WO2009032223A1 (en) 2009-03-12
MX2010002392A (es) 2010-07-28
EP2200617A4 (en) 2011-01-12
US20090061020A1 (en) 2009-03-05
CA2698680A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
CN101808645A (zh) 治疗红斑的改良溴莫尼定组合物
ES2812532T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir la rosácea
JP5580210B2 (ja) 手術前治療
RU2538729C2 (ru) Применение агонистов альфа 2 адренергических рецепторов для лечения или предотвращения псориаза
RU2587041C2 (ru) Способ предотвращения или лечения опухоли кожи
EP2481412B1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
JP2010537988A5 (enExample)
KR20230146513A (ko) 항진균 특성을 갖는 국소 로플루밀라스트 제형
US9078869B2 (en) Method for treating skin inflammatory diseases
HK1220637A1 (zh) 治疗皮肤增厚的方法
KR20140091543A (ko) 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
KR20140091544A (ko) 모세혈관종 치료방법
US11957669B2 (en) Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
CN102631567A (zh) 一种复方阿普洛尔纳米乳抗高血压药物
HK1175698B (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
CN108883056A (zh) 用于治疗外周关节、脊柱关节和/或结缔组织的细胞外基质元件的制剂、制造方法和用途
HK1204996B (en) Compounds, formulations, and methods for treating or preventing rosacea

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20100818